PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
News|Articles|March 4, 2026
Technological Renaissance: AI’s Integration into the Pharmaceutical Industry
As AI rapidly reshapes drug development and clinical operations, industry leaders say transparency, governance, and strong data foundations will determine whether the technology accelerates innovation or stalls under regulatory and operational pressure.
Advertisement
Advertisement
Artificial intelligence, once viewed as a distant promise within the pharmaceutical industry, has accelerated its way into operational reality.
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Lilly’s Foundayo receives a positive CHMP opinion for obesity and type 2 diabetes — putting the oral GLP-1 pill on course for EU approval.
The interleukin-6 receptor inhibitor gains a second indication, though one of two phase 3 trials missed its primary endpoint.
European regulators are increasing pressure on clinical trial sponsors to report study results on time, rolling out new monitoring, reminders and guidance as patient advocates welcome the progress but question whether stronger oversight and enforcement will follow.
Advertisement
Advertisement